Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation.

Trial Profile

An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Ception Therapeutics

Most Recent Events

  • 23 Feb 2010 Status changed from recruiting to completed based on Cephalon/Ception Therapeutics media release.
  • 23 Feb 2010 Results reported in a Cephalon/Ception Therapeutics media release.
  • 11 Sep 2009 Additional lead trial investigator (Fahrenholz JM) added as reported by Vanderbilt University Institutional Review Board.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top